SITC published its first CPG on immunotherapy for the treatment of renal cell carcinoma in the Journal for ImmunoTherapy of Cancer (JITC) on November 15, 2016.
Due to many advancements in immuno-oncology for the treatment of renal cell carcinoma, the SITC Renal Cell Carcinoma Expert Panel reconvened, developed, and published an updated CPG on immunotherapy for the treatment of advanced renal cell carcinoma in JITC on December 20, 2019.
SITC continuously evaluates the field for practice-changing data and new FDA approvals. When needed, the RCC CPG Expert Panel guides the development of updates within this CPG. Updates appear in the SITC CPG Mobile App and as annotated text accompanying the original publication in JITC.
Highlights of Updated Content:
*Updated narrative txt and recommendations based on approval of pembrolizumab for adjuvant treatment of RCC.
*Updated narrative text, tables, recommendations, and treatment algorithm based on approvals of pembrolizumab in combination with lenvatinib and nivolumab in combination with cabozantinib.